Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Published:2021-10 Issue:10 Volume:22 Page:1403-1415
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Schuster Stephen J,Tam Constantine S,Borchmann Peter,Worel Nina,McGuirk Joseph P,Holte Harald,Waller Edmund K,Jaglowski Samantha,Bishop Michael R,Damon Lloyd E,Foley Stephen Ronan,Westin Jason R,Fleury Isabelle,Ho P Joy,Mielke Stephan,Teshima Takanori,Janakiram Murali,Hsu Jing-Mei,Izutsu Koji,Kersten Marie José,Ghosh Monalisa,Wagner-Johnston Nina,Kato Koji,Corradini Paolo,Martinez-Prieto Marcela,Han Xia,Tiwari Ranjan,Salles Gilles,Maziarz Richard T

Funder

Novartis Pharmaceuticals Corp

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial;Locke;Lancet Oncol,2019

3. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

5. Chimeric antigen receptor T cells in refractory B-cell lymphomas;Schuster;N Engl J Med,2017

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy;Blood Advances;2024-09-24

2. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

3. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

4. Radiation Therapy Dose Response in Bulky Relapsed/Refractory Large B-Cell Lymphoma;Practical Radiation Oncology;2024-09

5. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial;Blood Neoplasia;2024-09